Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
about
The use of the tyrosine kinase inhibitor Nilotinib in Spondyloarthritis: does targeting inflammatory pathways with a treatment lead to vascular toxicity?Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
P2860
Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Nilotinib-induced vasculopathy ...... ells as a primary target site.
@en
Nilotinib-induced vasculopathy ...... ells as a primary target site.
@nl
type
label
Nilotinib-induced vasculopathy ...... ells as a primary target site.
@en
Nilotinib-induced vasculopathy ...... ells as a primary target site.
@nl
prefLabel
Nilotinib-induced vasculopathy ...... ells as a primary target site.
@en
Nilotinib-induced vasculopathy ...... ells as a primary target site.
@nl
P2093
P2860
P50
P356
P1433
P1476
Nilotinib-induced vasculopathy ...... cells as a primary target site
@en
P2093
G H Schernthaner
G Hoermann
R Kirchmair
S Herndlhofer
P2860
P2888
P304
P356
10.1038/LEU.2017.245
P50
P577
2017-07-31T00:00:00Z